|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00512 GRAND PHARMA
Nominal 
6.780 +0.200 (+3.040%) | 2025/12 - Final HKD(K$) | %Chg (Compare to Final) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | |
| Turnover | 12,283,271 | 5.482% | 11,644,892 | 10,529,590 | 9,562,285 | 8,597,975 |
| Cost of Sales | (5,502,910) | 12.154% | (4,906,576) | (4,005,524) | (3,610,806) | (3,350,737) |
| Gross Profit | 6,780,361 | 0.624% | 6,738,316 | 6,524,066 | 5,951,479 | 5,247,238 |
| 2025/12 - Final HKD(K$) | %Chg (Compare to Final) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (189,313) | -- | 599,472 | 18,763 | (91,345) | (8,350) | |
| Profit / (Loss) on Disposal | (38,718) | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | (73,378) | (58,664) | 23,017 | 484,495 | |
| Share of Results of Asso. & JCEs | 76,059 | -48.858% | 148,720 | (25,008) | (43,786) | 113,862 | |
| Profit / (Loss) before Taxation | 1,494,081 | -47.620% | 2,852,363 | 2,344,197 | 2,516,893 | 2,785,832 | |
| Taxation | (249,778) | -35.342% | (386,304) | (448,755) | (418,642) | (380,800) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (3,432) | -- | 2,316 | (15,444) | (18,832) | (2,469) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,240,871 | -49.729% | 2,468,375 | 1,879,998 | 2,079,419 | 2,402,563 | |
| 2025/12 - Final HKD(K$) | %Chg (Compare to Final) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | |
| Net Finance Costs / (Income) | 162,338 | -6.666% | 173,932 | 197,400 | 117,687 | 18,011 |
| Depreciation & Amortisation | 581,895 | 15.513% | 503,748 | 392,210 | 394,912 | 339,519 |
| Directors' Emoluments | -- | -- | 5,900 | 8,988 | 6,357 | 4,554 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 35.440 | -49.723% | 70.490 | 53.600 | 58.700 | 67.720 |
| DPS (cts) | 16.900 | -- | 26.000 | 26.000 | 14.000 | 11.000 |
| Dividend Payout Ratio (%) | 47.686% | -- | 36.885% | 48.507% | 23.850% | 16.243% |
| Cash flow per share ($) | -- | -- | 0.542 | 0.691 | 0.520 | 0.565 |
| NBV per share ($) | 4.794 | -- | 4.641 | 4.270 | 3.984 | 3.773 |
| Remarks: | Real time quote last updated: 27/03/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K$) | HKD 1,240,871 |
| %Change | -49.729% |
| EPS / (LPS) | HKD 0.354 |
| NBV Per Share ($) | HKD 4.794 |